| Type: | combo |
| Component1: | Salbutamol |
| Class1: | Beta2-adrenergic agonist |
| Component2: | Budesonide |
| Class2: | Corticosteroid |
| Tradename: | Airsupra |
| Dailymedid: | Albuterol and budesonide |
| Routes Of Administration: | Inhalation |
| Atc Prefix: | R03 |
| Atc Suffix: | AK15 |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Kegg: | D12757 |
| Synonyms: | PT027, albuterol/budesonide |
Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma.[2] It is a combination of salbutamol sulfate (albuterol sulfate), a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. It is inhaled using a pressurized metered-dose inhaler.
The most common side effects include headache, oral candidiasis, cough, and difficulty speaking.
Salbutamol/budesonide was approved for medical use in the United States in January 2023.[3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA). It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma.
Salbutamol/budesonide is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks.
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study.